Genvoya Tablet
Product Images NDC 61958-1901

5 FDA label images from Gilead Sciences, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Genvoya (NDC 61958-1901). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Genvoya 01)

Chemical Structure (Genvoya 01)
Chemical structure of the active ingredient elvitegravir, showing its molecular formula with rings and functional groups including hydroxyl, carbonyl, and methoxy groups, as well as chlorine and fluorine substitutions.*
FDA Label Image

Chemical Structure (Genvoya 02)

Chemical Structure (Genvoya 02)
Chemical structure of the active ingredients in Genvoya, showing molecular components of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. The diagram depicts bond connections and functional groups characteristic of these compounds.*
FDA Label Image

Chemical Structure (Genvoya 03)

Chemical Structure (Genvoya 03)
Chemical structure of tenofovir alafenamide, one of the active ingredients in Genvoya tablets, showing the molecular arrangement including nitrogen, fluorine, oxygen, sulfur, and carbon atoms.*
FDA Label Image

Chemical Structure (Genvoya 04)

Chemical Structure (Genvoya 04)
Chemical structure of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide ingredients as depicted in a molecular diagram. The structure shows key atomic arrangements and bonds consistent with the active components of Genvoya tablets.*
FDA Label Image

Principal Display Panel (30 Tablet Bottle Label)

Principal Display Panel (30 Tablet Bottle Label)
Label of Genvoya tablets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide. The oral tablet package contains 30 tablets and is manufactured by Gilead Sciences, Inc. The label includes storage instructions, safety warnings, and a note to pharmacists not to cover ALERT information with the pharmacy label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.